Delta Radiomic Analysis of Mesorectum to Predict Treatment Response and Prognosis in Locally Advanced Rectal Cancer.
early regression index
high-risk factors
mesorectal fact signatures
predictive models
radiomics
rectal cancer
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
07 Jun 2023
07 Jun 2023
Historique:
received:
28
04
2023
revised:
23
05
2023
accepted:
31
05
2023
medline:
28
6
2023
pubmed:
28
6
2023
entrez:
28
6
2023
Statut:
epublish
Résumé
The aim of this study is to evaluate the delta radiomics approach based on mesorectal radiomic features to develop a model for predicting pathological complete response (pCR) and 2-year disease-free survival (2yDFS) in locally advanced rectal cancer (LARC) patients undergoing neoadjuvant chemoradiotherapy (nCRT). Pre- and post-nCRT MRIs of LARC patients treated at a single institution from May 2008 to November 2016 were retrospectively collected. Radiomic features were extracted from the GTV and mesorectum. The Wilcoxon-Mann-Whitney test and area under the receiver operating characteristic curve (AUC) were used to evaluate the performance of the features in predicting pCR and 2yDFS. Out of 203 LARC patients, a total of 565 variables were evaluated. The best performing pCR prediction model was based on two GTV features with an AUC of 0.80 in the training set and 0.69 in the validation set. The best performing 2yDFS prediction model was based on one GTV and two mesorectal features with an AUC of 0.79 in the training set and 0.70 in the validation set. The results of this study suggest a possible role for delta radiomics based on mesorectal features in the prediction of 2yDFS in patients with LARC.
Sections du résumé
BACKGROUND
BACKGROUND
The aim of this study is to evaluate the delta radiomics approach based on mesorectal radiomic features to develop a model for predicting pathological complete response (pCR) and 2-year disease-free survival (2yDFS) in locally advanced rectal cancer (LARC) patients undergoing neoadjuvant chemoradiotherapy (nCRT).
METHODS
METHODS
Pre- and post-nCRT MRIs of LARC patients treated at a single institution from May 2008 to November 2016 were retrospectively collected. Radiomic features were extracted from the GTV and mesorectum. The Wilcoxon-Mann-Whitney test and area under the receiver operating characteristic curve (AUC) were used to evaluate the performance of the features in predicting pCR and 2yDFS.
RESULTS
RESULTS
Out of 203 LARC patients, a total of 565 variables were evaluated. The best performing pCR prediction model was based on two GTV features with an AUC of 0.80 in the training set and 0.69 in the validation set. The best performing 2yDFS prediction model was based on one GTV and two mesorectal features with an AUC of 0.79 in the training set and 0.70 in the validation set.
CONCLUSIONS
CONCLUSIONS
The results of this study suggest a possible role for delta radiomics based on mesorectal features in the prediction of 2yDFS in patients with LARC.
Identifiants
pubmed: 37370692
pii: cancers15123082
doi: 10.3390/cancers15123082
pmc: PMC10296157
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Cancer Med. 2020 Jan;9(1):361-373
pubmed: 31693304
Radiother Oncol. 2021 Jan;154:154-160
pubmed: 32966845
Lancet Oncol. 2020 May;21(5):e252-e264
pubmed: 32359501
Bull Cancer. 2022 Dec;109(12):1269-1276
pubmed: 35870953
Oncol Res Treat. 2020;43(4):146-152
pubmed: 32036373
J Magn Reson Imaging. 2018 Feb 13;:
pubmed: 29437271
Annu Int Conf IEEE Eng Med Biol Soc. 2015 Aug;2015:771-4
pubmed: 26736376
Front Oncol. 2020 Dec 03;10:595012
pubmed: 33344243
Ann Surg. 2022 Aug 1;276(2):334-344
pubmed: 32941279
Front Oncol. 2020 Apr 09;10:459
pubmed: 32328461
Radiol Med. 2021 Mar;126(3):421-429
pubmed: 32833198
Ann Surg Oncol. 2012 Sep;19(9):2822-32
pubmed: 22434243
N Engl J Med. 2004 Oct 21;351(17):1731-40
pubmed: 15496622
Int J Mol Sci. 2017 Mar 07;18(3):
pubmed: 28272347
Radiol Med. 2018 Apr;123(4):286-295
pubmed: 29230678
Clin Transl Radiat Oncol. 2023 Jan 12;39:100579
pubmed: 36935859
Clin Cancer Res. 2017 Dec 1;23(23):7253-7262
pubmed: 28939744
Radiol Med. 2022 Jan;127(1):11-20
pubmed: 34725772
Invest Radiol. 2015 Apr;50(4):239-45
pubmed: 25501017
Lancet Oncol. 2015 Aug;16(8):979-89
pubmed: 26189067
Semin Oncol. 2020 Feb;47(1):85-92
pubmed: 32147127
Biochim Biophys Acta Rev Cancer. 2020 Aug;1874(1):188386
pubmed: 32540465
Abdom Radiol (NY). 2021 Mar;46(3):873-884
pubmed: 32940755
Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):765-774
pubmed: 29891200
Ann Surg Oncol. 2010 Jun;17(6):1471-4
pubmed: 20180029
Eur Radiol. 2020 Nov;30(11):6263-6273
pubmed: 32500192
Eur J Surg Oncol. 2014 Apr;40(4):469-75
pubmed: 24439446
Phys Med. 2021 Apr;84:186-191
pubmed: 33901863
Radiology. 2018 Jun;287(3):833-843
pubmed: 29514017
Artif Intell Med. 2019 May;96:145-153
pubmed: 30292538
Lancet Oncol. 2015 Aug;16(8):957-66
pubmed: 26187751
Cancers (Basel). 2022 Mar 24;14(7):
pubmed: 35406415
Ann Intern Med. 2015 May 19;162(10):735-6
pubmed: 25984857
Int J Radiat Oncol Biol Phys. 2020 Dec 1;108(5):1347-1356
pubmed: 32758641
Eur Radiol. 2019 Mar;29(3):1211-1220
pubmed: 30128616
Lancet Oncol. 2011 Jun;12(6):575-82
pubmed: 21596621
Front Oncol. 2022 Feb 24;12:831712
pubmed: 35280799
Radiother Oncol. 2018 Sep;128(3):564-568
pubmed: 30196982
N Engl J Med. 2001 Aug 30;345(9):638-46
pubmed: 11547717
Clin Colorectal Cancer. 2022 Mar;21(1):10-18
pubmed: 34895835
Clin Transl Radiat Oncol. 2019 Jul 03;19:12-16
pubmed: 31334366
Radiother Oncol. 2019 May;134:110-118
pubmed: 31005204
Radiology. 2018 Jul;288(1):129-137
pubmed: 29558294
Radiother Oncol. 2016 Aug;120(2):195-201
pubmed: 27528121
Biometrics. 1988 Sep;44(3):837-45
pubmed: 3203132
Ann Oncol. 2017 Jul 1;28(suppl_4):iv22-iv40
pubmed: 28881920
Eur Radiol. 2022 Feb;32(2):971-980
pubmed: 34327580
Cancer. 1994 Jun 1;73(11):2680-6
pubmed: 8194005
Radiother Oncol. 2008 Dec;89(3):347-52
pubmed: 18762345